MX2013004491A - Boronatos como inhibidores de arginasa. - Google Patents

Boronatos como inhibidores de arginasa.

Info

Publication number
MX2013004491A
MX2013004491A MX2013004491A MX2013004491A MX2013004491A MX 2013004491 A MX2013004491 A MX 2013004491A MX 2013004491 A MX2013004491 A MX 2013004491A MX 2013004491 A MX2013004491 A MX 2013004491A MX 2013004491 A MX2013004491 A MX 2013004491A
Authority
MX
Mexico
Prior art keywords
sup
boronates
arginase inhibitors
arginase
activity
Prior art date
Application number
MX2013004491A
Other languages
English (en)
Other versions
MX336381B (es
Inventor
Michael Van Zandt
Erik Jagdmann Gunnar Jr
Original Assignee
Mars Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mars Inc filed Critical Mars Inc
Publication of MX2013004491A publication Critical patent/MX2013004491A/es
Publication of MX336381B publication Critical patent/MX336381B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Los compuestos de acuerdo con la Fórmula I son inhibidores potentes de la actividad de arginasa I y II: (I) en donde R1, R2, R3, R4, D, W, X, Y, y Z se definen en la especificación. La invención también proporciona las composiciones farmacéuticas de los compuestos y los métodos de su uso en el tratamiento o prevención de una enfermedad o una condición asociada con la actividad de arginasa.
MX2013004491A 2010-10-26 2011-10-19 Boronatos como inhibidores de arginasa. MX336381B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40676010P 2010-10-26 2010-10-26
PCT/US2011/056844 WO2012058065A1 (en) 2010-10-26 2011-10-19 Boronates as arginase inhibitors

Publications (2)

Publication Number Publication Date
MX2013004491A true MX2013004491A (es) 2013-11-04
MX336381B MX336381B (es) 2016-01-18

Family

ID=44913403

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004491A MX336381B (es) 2010-10-26 2011-10-19 Boronatos como inhibidores de arginasa.

Country Status (19)

Country Link
US (5) US9233985B2 (es)
EP (3) EP3034509B1 (es)
JP (1) JP5909239B2 (es)
CN (2) CN103249737B (es)
AU (1) AU2011320732B2 (es)
BR (1) BR112013010099B1 (es)
CA (1) CA2815536C (es)
DK (1) DK2632927T3 (es)
ES (2) ES2568680T3 (es)
HK (2) HK1223104A1 (es)
HR (1) HRP20160305T1 (es)
HU (1) HUE027317T2 (es)
IL (1) IL225926A (es)
MX (1) MX336381B (es)
PL (1) PL2632927T3 (es)
RS (1) RS54750B1 (es)
SI (1) SI2632927T1 (es)
SM (1) SMT201600141B (es)
WO (1) WO2012058065A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2586219C2 (ru) 2010-04-22 2016-06-10 Марс, Инкорпорейтед Ингибиторы аргиназы и их терапевтические применения
PL2603514T3 (pl) 2010-08-10 2019-04-30 Rempex Pharmaceuticals Inc Cykliczne pochodne estrowe kwasu boronowego oraz ich zastosowania terapeutyczne
ES2568680T3 (es) 2010-10-26 2016-05-03 Mars, Incorporated Boratos como inhibidores de arginasa
EP2852598B3 (en) * 2012-04-18 2016-10-19 Mars, Incorporated Ring constrained analogs as arginase inhibitors
WO2014107535A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2944903A1 (en) 2014-04-24 2015-10-29 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
EP4356736A2 (en) 2014-05-05 2024-04-24 Melinta Therapeutics, Inc. Synthesis of boronate salts
EP3139930A4 (en) 2014-05-05 2018-01-17 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
KR20170007448A (ko) 2014-05-19 2017-01-18 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
CA2952968A1 (en) 2014-07-01 2016-01-07 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
PL410665A1 (pl) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP2018520352A (ja) 2015-06-23 2018-07-26 カリセラ バイオサイエンシズ，インコーポレイテッド アルギナーゼ活性を阻害するための組成物および方法
RU2729379C1 (ru) 2015-10-01 2020-08-06 Потенза Терапевтикс, Инк. Анти-tigit антигенсвязывающие белки и способы их применения
KR20220118559A (ko) * 2015-10-30 2022-08-25 칼리테라 바이오사이언시즈, 인코포레이티드 아르기닌 활성 억제용 조성물 및 방법
PL417066A1 (pl) * 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
MY196909A (en) 2016-06-30 2023-05-09 Qpex Biopharma Inc Boronic acid derivatives and therapeutic uses thereof
WO2018089490A1 (en) * 2016-11-08 2018-05-17 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
DK3559009T3 (da) 2016-12-22 2021-05-03 Calithera Biosciences Inc Sammensætninger og metoder til inhibition af arginaseaktivitet
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
US10494339B2 (en) 2017-05-12 2019-12-03 Calithera Biosciences, Inc. Method of preparing (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide
US11286270B2 (en) 2017-10-11 2022-03-29 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
WO2019120296A1 (en) * 2017-12-22 2019-06-27 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as arginase inhibitors
UY38096A (es) 2018-02-17 2019-07-31 Astrazeneca Ab Inhibidores de arginasa y sus métodos de uso
JP7402167B2 (ja) * 2018-03-05 2023-12-20 アーカス バイオサイエンシズ インコーポレイティド アルギナーゼ阻害剤
EP3765006A4 (en) * 2018-03-13 2022-02-23 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE
WO2019186497A1 (en) 2018-03-29 2019-10-03 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
CN111770756B (zh) * 2018-04-27 2023-03-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途
WO2019218904A1 (zh) * 2018-05-18 2019-11-21 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、其制备方法及用途
US11274111B2 (en) 2018-06-20 2022-03-15 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
EP3880685A4 (en) 2018-11-16 2022-07-27 Arcus Biosciences, Inc. ARG1 AND/OR ARG2 INHIBITORS
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020131598A1 (en) * 2018-12-18 2020-06-25 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
WO2020160707A1 (en) * 2019-02-06 2020-08-13 Guangdong Newopp Biopharmaceuticals Co., Ltd. Alkylboronic acids as arginase inhibitors
CR20210463A (es) * 2019-02-08 2021-10-15 Astrazeneca Ab Inhibidores de arginasa y métodos de uso de estos
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
WO2021141751A1 (en) * 2020-01-07 2021-07-15 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
EP4175719A1 (en) 2020-07-02 2023-05-10 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
EP4298099A1 (en) 2021-02-25 2024-01-03 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
WO2023283332A1 (en) * 2021-07-07 2023-01-12 Emory University Uses of arginase inhibitors for managing kidney disease and cardiovascular conditions
WO2023191116A2 (en) 2022-01-21 2023-10-05 Opiyo Sammy Oyoo Improved suramin methods and compositions
WO2023178285A1 (en) 2022-03-17 2023-09-21 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1009890A (en) 1911-02-09 1911-11-28 Michael F Brauer Dumping attachment for headers.
US1006597A (en) 1911-05-26 1911-10-24 Rail Joint Co Insulated rail-joint.
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
CN1229110C (zh) 1997-07-29 2005-11-30 阿尔康实验室公司 含半乳甘露聚糖聚合物和硼酸盐的眼用组合物
CA2305703A1 (en) * 1997-10-10 1999-04-22 David W. Christianson Compositions and methods for inhibiting arginase activity
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
EP1299398A1 (en) 2000-07-06 2003-04-09 Fal Diagnostics Methods and kits for the detection of arginine compounds
CA2431080A1 (en) 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1915143A4 (en) 2005-07-01 2009-11-11 Univ Johns Hopkins ARGINASE II: TARGET TREATMENT FOR THE AGING HEART AND HEART FAILURE
US20100056480A1 (en) 2006-11-21 2010-03-04 Rijks Univesiteit Groningen Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
JP5386353B2 (ja) 2007-07-12 2014-01-15 山洋電気株式会社 二重反転式軸流送風機
EP2214660A2 (en) 2007-10-12 2010-08-11 Resolvyx Pharmaceuticals, Inc. Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for the treatment of ophthalmic conditions
MX2010012064A (es) 2008-05-05 2010-12-06 Schering Corp Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.
DK2389352T3 (da) 2009-01-26 2019-07-29 Univ Pennsylvania Arginaseinhibitorer og anvendelsesfremgangsmåder
RU2586219C2 (ru) 2010-04-22 2016-06-10 Марс, Инкорпорейтед Ингибиторы аргиназы и их терапевтические применения
ES2568680T3 (es) 2010-10-26 2016-05-03 Mars, Incorporated Boratos como inhibidores de arginasa
EP2658580A4 (en) 2010-12-31 2014-07-23 Corridor Pharmaceuticals Inc ARGINE STARTER AND USE METHOD
AU2012326109A1 (en) 2011-10-19 2014-05-29 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
AU2012325909B2 (en) 2011-10-20 2016-06-09 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
EP2852598B3 (en) 2012-04-18 2016-10-19 Mars, Incorporated Ring constrained analogs as arginase inhibitors
BR112015010059A2 (pt) 2012-11-02 2017-07-11 Pharmacyclics Inc terapia adjuvante com inibidor da quinase da família tec
ES2719327T3 (es) 2013-07-01 2019-07-09 Bristol Myers Squibb Co Inhibidores de IDO
CN105848680A (zh) 2013-10-25 2016-08-10 药品循环有限责任公司 使用布鲁顿酪氨酸激酶抑制剂和免疫疗法的治疗
CN105879030A (zh) 2014-09-30 2016-08-24 复旦大学 ***的增效药物复合物及其制备方法
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
KR20170129896A (ko) 2015-03-20 2017-11-27 새미 오유 오피요 악성 신생물에 대한 수라민 및 아르기나아제 억제제의 용도
JP2018520352A (ja) 2015-06-23 2018-07-26 カリセラ バイオサイエンシズ，インコーポレイテッド アルギナーゼ活性を阻害するための組成物および方法
KR20220118559A (ko) 2015-10-30 2022-08-25 칼리테라 바이오사이언시즈, 인코포레이티드 아르기닌 활성 억제용 조성물 및 방법
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
DK3559009T3 (da) 2016-12-22 2021-05-03 Calithera Biosciences Inc Sammensætninger og metoder til inhibition af arginaseaktivitet
US10494339B2 (en) 2017-05-12 2019-12-03 Calithera Biosciences, Inc. Method of preparing (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide

Also Published As

Publication number Publication date
CN106008569B9 (zh) 2020-05-22
US11389464B2 (en) 2022-07-19
SI2632927T1 (sl) 2016-08-31
HUE027317T2 (en) 2016-10-28
US20150191492A1 (en) 2015-07-09
HRP20160305T1 (hr) 2016-07-01
SMT201600141B (it) 2016-07-01
RS54750B1 (sr) 2016-10-31
WO2012058065A1 (en) 2012-05-03
EP2632927A1 (en) 2013-09-04
US20120129806A1 (en) 2012-05-24
EP3034509B1 (en) 2020-04-22
HK1225390A1 (zh) 2017-09-08
ES2568680T3 (es) 2016-05-03
US9440995B2 (en) 2016-09-13
JP2013542223A (ja) 2013-11-21
JP5909239B2 (ja) 2016-04-26
US10098902B2 (en) 2018-10-16
CA2815536A1 (en) 2012-05-03
EP3719024A1 (en) 2020-10-07
US10603330B2 (en) 2020-03-31
US20200246362A1 (en) 2020-08-06
CN106008569B (zh) 2020-04-03
BR112013010099A2 (pt) 2016-09-06
IL225926A0 (en) 2013-06-27
PL2632927T3 (pl) 2016-09-30
IL225926A (en) 2016-09-29
AU2011320732B2 (en) 2018-07-05
CN103249737A (zh) 2013-08-14
US9233985B2 (en) 2016-01-12
US20190054101A1 (en) 2019-02-21
CN103249737B (zh) 2016-06-08
AU2011320732A1 (en) 2013-11-21
BR112013010099B1 (pt) 2021-08-10
EP2632927B1 (en) 2016-02-10
HK1223104A1 (zh) 2017-07-21
MX336381B (es) 2016-01-18
DK2632927T3 (en) 2016-04-11
EP3034509A1 (en) 2016-06-22
CN106008569A (zh) 2016-10-12
US20170000808A1 (en) 2017-01-05
ES2794006T3 (es) 2020-11-17
CA2815536C (en) 2019-10-01

Similar Documents

Publication Publication Date Title
MX2013004491A (es) Boronatos como inhibidores de arginasa.
MX348422B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
MA33939B1 (fr) 5-alcynyl-pyrimidines
CA2871471C (en) Dna-pk inhibitors
MX2013006802A (es) Inhibidores de neprilisina.
MY165087A (en) Neprilysin inhibitors
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
MY170935A (en) Neprilysin inhibitors
PH12015500260A1 (en) Neprilysin inhibitors
MA34069B1 (fr) Dérivés de n-(imidazopyrimidin-7-yl)hétéroarylamide et leur utilisation comme inhibiteurs de pde10a)
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MX2013008212A (es) Derivados de 7-azaindol.
MX2013000821A (es) Nuevas aminopirazoloquinazolinas.
MD4556C1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
MX2012014017A (es) Derivados de heteroaril imidazolona como inhibidores de jak.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MY148732A (en) Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
MY152685A (en) Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments
MX2013006670A (es) Derivado de 2-carboxamida-4-piperazinil-benzofurano.
MY152040A (en) Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
TN2012000370A1 (en) 5-alkynyl pyrimidines and their use as kinase inhibitors
TN2013000150A1 (en) Co-crystals and salts of ccr3-inhibitors
UA99734C2 (ru) Производные азабифениламинобензойной кислоты как ингибиторы dhodh